Nuplazid Approved For Treatment Of Parkinsons Disease
The United States Food and Drug Administration (FDA) has approved Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the first FDA-approved treatment specifically for this condition, which affects approximately 40% of people with Parkinson's disease. The approval was based on the results of two Phase 3 clinical trials that showed Nuplazid was effective in reducing hallucinations and delusions in people with Parkinson's disease psychosis.
Nuplazid Approved For Treatment Of Parkinson's Disease
The U.S. Food and Drug Administration (FDA) has approved Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the first and only medication approved by the FDA specifically for this indication.Parkinson's disease is a progressive neurological disorder that affects movement, balance, and coordination. It is the second most common neurodegenerative disorder after Alzheimer's disease. Parkinson's disease psychosis is a common non-motor symptom of Parkinson's disease, affecting up to 50% of patients. Hallucinations and delusions are the most common psychotic symptoms, and they can be very distressing for patients and their caregivers.Nuplazid is a selective serotonin inverse agonist that is thought to work by blocking the activity of serotonin receptors in the brain. This is believed to reduce the hallucinations and delusions associated with Parkinson's disease psychosis.
Nuplazid: A Safe and Effective Treatment
Nuplazid is a safe and effective treatment for hallucinations and delusions associated with Parkinson's disease psychosis. In clinical trials, Nuplazid was shown to significantly reduce the frequency and severity of hallucinations and delusions. Nuplazid was also well-tolerated, with the most common side effects being nausea, constipation, and dizziness.Nuplazid is a major breakthrough in the treatment of Parkinson's disease psychosis. It is the first and only medication approved by the FDA specifically for this indication, and it has been shown to be safe and effective. Nuplazid offers hope to the millions of people who suffer from Parkinson's disease psychosis.
How to Take Nuplazid
Nuplazid is taken orally, once daily. The recommended starting dose is 1 mg per day. The dose may be increased to 2 mg per day if needed. Nuplazid should be taken with food.Nuplazid is contraindicated in patients with a history of hypersensitivity to the drug. It is also contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). Nuplazid should be used with caution in patients with a history of seizures or other neurological disorders.
Nuplazid is a safe and effective treatment for hallucinations and delusions associated with Parkinson's disease psychosis. It is the first and only medication approved by the FDA specifically for this indication. Nuplazid offers hope to the millions of people who suffer from Parkinson's disease psychosis.
